The present invention is the use of designed recombinant viruses for the treatment of various forms of malignant tumors. The recombinant viruses of the invention are those in which one or more regions of the wild type virus was exchanged with a synthetic recoded sequence that reduces the codon pair score relative to human codon pair bias, or that increase the number for CpG di-nucleotides, or that increases the number of UpA di-nucleotides. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, as well as for the treatment of breast cancer and melanoma as well.

Disclosed are delivery and expression systems of multiple antiviral therapeutic molecules. The therapeutic molecules include a novel class of dual-functional peptide and defective interfering genes of a virus. Also disclosed are compositions comprising the therapeutic molecules that are useful for the treatment and prevention of viral infections. Also disclosed herein are the method of making and using a vector that expresses the therapeutic molecules. Therapeutic molecules include cellular components such as RNA, DNA, peptide, proteins or combination thereof.

The invention relates to defective interfering viruses and defective interfering virus RNAs that are effective as antiviral agents. The invention also relates to methods for identifying defective interfering virus RNAs that can be used as effective antiviral agents.

This invention provides tools and methods that prevent a cancer cell from growing and reproducing more cancer cells in a diseased animal. When growth ceases the body's immune defenses are enabled to attack and destroy these cells if the cancer cell itself has not initiated its own natural apoptotic self-destruction processes. The tools and methods of the invention obstruct the metabolic adaptions required to support cancer growth. By addressing the increased rates of metabolism characteristic of all rapidly reproducing cancer cells using chemical and/or physical nanotechnology to identify, segregate, isolate these hypermetabolizing cells, the body's immune system and other natural defenses are empowered to further isolate and eliminate the diseased cells. The extreme growth rates required for their rapid reproduction involve massively increased rates of the biochemical reactions supporting the cancerous growth. Each excess reaction produces extra heat and raises the internal cell's temperature and the tissue space immediate to the rapidly growing cells. This heat signature is used as a primary biomarker that enables binding of a nanoviral particle engineered to migrate to at attach at the target site at the site and prevent the cell from continued metabolism. Preferably, the nanoparticle not only binds and blocks external membrane receptors on the target cell, but incorporates into the rapidly metabolizing cells additional metabolic blocking agents to stop their growth. When cell growth and proliferation are stopped, the body's natural defenses are able to segregate and eliminate these cells. The massively increased rates of metabolic reactions characteristic of cancer cells also produce excess acid. The decreased pH is useful as a secondary or confirmatory marker for identifying these cancer cells.

The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS1 protein, wherein the vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing the influenza virus vector, its use for the treatment of cancer patients and methods for producing the influenza virus vaccine.

In The present invention relates in a first aspect to the use of influenza virus defective interfering particles in the prophylactic or therapeutic treatment of coronaviridae infection. In particular, it has been recognized that defective interfering particles of influenza A have beneficial effects in the treatment of SARS coronavirus infection, in particular, SARS-CoV-2 infection. Further, the present invention relates to a pharmaceutical composition for use in treating coronaviridae infection, in particular SARS-CoV-2. In a further aspect, methods for the prophylactic or therapeutic treatments of coronaviridae based on the administration of DIFs are disclosed.

The present invention relates to a nanoperforator having a lipid-bilayer nanodisc and a membrane-structured protein surrounding the nanodisc and to a pharmaceutical composition having the nanoperforator as an active ingredient for preventing or treating viral infectious diseases. The use of the lipid-bilayer nanoperforator provided in the present invention can lead to the safe prevention or treatment of a disease caused by viral infection regardless of whether the virus is a variant or not, and thus the present invention can be widely used for the safe and effective treatment of viral infectious diseases.

RNA virus vectors comprising a gene encoding the DNA-dependent activator of interferon-regulatory factors (DAI) protein, and optionally further comprising a gene encoding the receptor-interacting serine/threonine-protein kinase 3 (RIPK3) may be used therapeutically to induce cell death, as well as an inflammatory immune response, against tumors and virally-infected cells.

A system and method that identifies and causes cancerous cells to self-destruct by using an engineered virus to vector and distinguish cancerous cells from normal cells through metabolic and other biometric signatures inherent in cancerous cells, identifies, binds and inserts itself into the cancer cell thereby causing the cell to identify and highlight itself as a target for natural intracellular and systemic cell-eradication pathways. Upon confirmatory binding, these engineered vectors, that specifically identify and target only cancer cells through binding to and then being absorbed into the cancer cells, fix the body's natural defenses that cancer cells evaded as part of cancer's progression to activate multiple paths for precisely targeted destruction of the hyperproliferating cells. In the development stages, the cancer cell must intensify its metabolism to support the prolific growth and at the same time the transforming cell must debilitate the intracellular and systemic checks against uncontrolled cell growth that the body has developed to maintain homeostasis. The vector of this invention is engineered to identify and bind cells expressing the intensified metabolic signatures required for cancer's growth, and then by inserting into the cell, to trigger natural intracellular defenses that, in responding to the vector, also prevent continuing metabolism of the cancer cell. The vector initiates dormant metabolic pathways that will, when activated, support eradication of the targeted cell through its natural apoptosis. Several of the compounds induced in response to the vector entry into the target cell also unleash a systemic effect by migrating to the cell membrane where: a) they serve as tags or markers of the infected cell; and b) by releasing cytokines, guide powerful killing cells from the immune system to the tagged cell. These natural processes provide additional backup measures to complete the destruction and removal of the targeted cancer cell.

In a first aspect, the present invention relates to a method for the purification of virus compositions as well as biological macromolecular compounds in a sample comprising mixing the sample with osmolytes, like non-ionic organic polymers and contacting the mixed sample with a hydrophilic membrane, optionally washing the membrane,and eluting the virus preparations or biological macromolecular components from the membrane with an eluting solution containing reduced amounts or no osmolytes, like non-ionic organic polymer. Moreover, virus compositions and biological macromolecular components obtainable with the method according to the present invention are provided as well as the use of the method according to the present invention for purification of virus compositions including whole virus particles and virus-like particles or biological macromolecular components.